Try our beta test site

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.
ClinicalTrials.gov Identifier:
NCT01159028
First received: July 7, 2010
Last updated: January 30, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)